AGL 39.58 Decreased By ▼ -0.42 (-1.05%)
AIRLINK 131.22 Increased By ▲ 2.16 (1.67%)
BOP 6.81 Increased By ▲ 0.06 (0.89%)
CNERGY 4.71 Increased By ▲ 0.22 (4.9%)
DCL 8.44 Decreased By ▼ -0.11 (-1.29%)
DFML 41.47 Increased By ▲ 0.65 (1.59%)
DGKC 82.09 Increased By ▲ 1.13 (1.4%)
FCCL 33.10 Increased By ▲ 0.33 (1.01%)
FFBL 72.87 Decreased By ▼ -1.56 (-2.1%)
FFL 12.26 Increased By ▲ 0.52 (4.43%)
HUBC 110.74 Increased By ▲ 1.16 (1.06%)
HUMNL 14.51 Increased By ▲ 0.76 (5.53%)
KEL 5.19 Decreased By ▼ -0.12 (-2.26%)
KOSM 7.61 Decreased By ▼ -0.11 (-1.42%)
MLCF 38.90 Increased By ▲ 0.30 (0.78%)
NBP 64.01 Increased By ▲ 0.50 (0.79%)
OGDC 192.82 Decreased By ▼ -1.87 (-0.96%)
PAEL 25.68 Decreased By ▼ -0.03 (-0.12%)
PIBTL 7.34 Decreased By ▼ -0.05 (-0.68%)
PPL 154.07 Decreased By ▼ -1.38 (-0.89%)
PRL 25.83 Increased By ▲ 0.04 (0.16%)
PTC 17.81 Increased By ▲ 0.31 (1.77%)
SEARL 82.30 Increased By ▲ 3.65 (4.64%)
TELE 7.76 Decreased By ▼ -0.10 (-1.27%)
TOMCL 33.46 Decreased By ▼ -0.27 (-0.8%)
TPLP 8.49 Increased By ▲ 0.09 (1.07%)
TREET 16.62 Increased By ▲ 0.35 (2.15%)
TRG 57.40 Decreased By ▼ -0.82 (-1.41%)
UNITY 27.51 Increased By ▲ 0.02 (0.07%)
WTL 1.37 Decreased By ▼ -0.02 (-1.44%)
BR100 10,504 Increased By 59.3 (0.57%)
BR30 31,226 Increased By 36.9 (0.12%)
KSE100 98,080 Increased By 281.6 (0.29%)
KSE30 30,559 Increased By 78 (0.26%)

A Philadelphia jury on Friday ordered pharmaceutical giant Pfizer to pay $6.3 million in compensatory damages to an Illinois breast cancer survivor after finding menopause drugs Premarin, Provera and Prempro caused the disease. The panel also found that punitive damages are warranted because of willful and wanton conduct by Pfizer units Wyeth and Pharmacia & Upjohn in failing to warn Donna Kendall about risks associated with the drugs, said her attorney Tobias Millrood.
The jury meets on Monday to decide on additional damages. The award is the largest so far of about three dozen Prempro cases tried in Philadelphia, out of about 1,500 pending lawsuits, Millrood said. Pfizer said it was "disappointed" by the verdict and would evaluate its legal options as soon as the case concludes.
The drug companies have prevailed in most hormone therapy cases spurred by the 2002 Women's Health Initiative finding that long-term use of the menopause drugs increases women's breast cancer and cardiovascular disease risks. Kendall, 66, of Decatur, Illinois, had been taking Wyeth's Prempro as well as Provera, sold by Pfizer's Phamacia unit for a total of 11 years when she was diagnosed with breast cancer in 2002, Millrood said.
Wyeth was the original defendant in hundreds of personal liability cases involving the hormone replacement therapy drugs. But with its $67 billion acquisition of that company, completed last month, Pfizer inherited Wyeth's legal headaches as well as its drug portfolio and promising pipeline. Wyeth and Pharmacia & Upjohn have argued at trial that the drugs were approved by the US Food and Drug Administration. The case is Kendall v. Wyeth et al, Philadelphia County Court of Common Pleas.

Copyright Reuters, 2009

Comments

Comments are closed.